Cost-Effectiveness of Olaratumab in Combination with Doxorubicin for Patients with Soft Tissue Sarcoma in the United States

BACKGROUND: Standard first-line treatments for advanced soft tissue sarcoma (STS) have changed little for 40 years, and outcomes have been poor. Recently, the United States (US) Food and Drug Administration conditionally approved olaratumab in combination with doxorubicin (Olara + Dox) based on a ra...

Descripción completa

Detalles Bibliográficos
Autores principales: Zuluaga-Sanchez, Santiago, Hess, Lisa M., Wolowacz, Sorrel E., D'yachkova, Yulia, Hawe, Emma, Vickers, Adrian D., Kaye, James A., Bertwistle, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5892240/
https://www.ncbi.nlm.nih.gov/pubmed/29785170
http://dx.doi.org/10.1155/2018/6703963

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5892240/
https://www.ncbi.nlm.nih.gov/pubmed/29785170
http://dx.doi.org/10.1155/2018/6703963

Ejemplares similares